


Reference Data

(Consolidated Financial Results for Q1 FY2017)



Daiichi-Sankyo

July 31, 2017

Daiichi Sankyo Co., Ltd.

<http://www.daiichisankyo.com>

Contents

1.	Consolidated Statement of Profit or Loss	P1
2.	Revenue of Global Products	P2
3.	Revenue by Business Units and Products	P3
4.	Consolidated Statement of Financial Position	P6
5.	Consolidated Statement of Cash Flows	P8
6.	Number of Employees	P9
7.	Capital Expenditure, Depreciation and Amortization	P9
8.	Summary of Product Outlines	P10
9.	Quarterly Data	P11
10.	Historical Data	P16
11.	Major R&D Pipeline (Innovative pharmaceuticals)	P20

1. Consolidated Statement of Profit or Loss

JPY Bn	FY2016 Q1		FY2017 Q1					FY2017			
	to revenue	Results	to revenue	Results	(vs. Forecast (%))	YoY	YoY (%)	to revenue	Forecast	YoY	YoY (%)
Revenue	100.0%	241.0	100.0%	239.1	(25.7%)	-1.9	-0.8%	100.0%	930.0	-25.1	-2.6%
Cost of sales	32.2%	77.6	33.5%	80.1	(23.6%)	2.5	+3.2%	36.6%	340.0	-9.4	-2.7%
(excl. Special items)	32.2%	77.6	33.5%	80.1		2.5	+3.2%				
(Special items)	-	-	-	-		-					
Gross Profit	67.8%	163.4	66.5%	159.0	(27.0%)	-4.3	-2.6%	63.4%	590.0	-15.8	-2.6%
SG&A expenses	28.8%	69.5	29.6%	70.8	(23.6%)	1.3	+1.8%	32.3%	300.0	-2.5	-0.8%
(excl. Special items)	28.8%	69.5	29.6%	70.8		1.3	+1.8%				
(Special items)	-	-	-	-		-					
R&D expenses	19.3%	46.6	20.1%	48.0	(25.3%)	1.4	+2.9%	20.4%	190.0	-24.3	-11.4%
(excl. Special items)	19.3%	46.6	20.1%	48.0		1.4	+2.9%				
(Special items)	-	-	-	-		-					
Operating Profit	19.6%	47.3	16.8%	40.3	(40.3%)	-7.0	-14.8%	10.8%	100.0	11.1	+12.4%
(Operating Profit before Special items)	19.6%	47.3	16.8%	40.3		-7.0	-14.8%				
Financial income/expenses		-1.9		2.1		3.9					
Share of profit or loss of investments accounted for using the equity method		-0.2		-0.1		0.1					
Profit before tax	18.8%	45.2	17.7%	42.2	(42.2%)	-3.0	-6.6%	10.8%	100.0	12.2	+13.9%
Income taxes		15.1		13.4		-1.7	-11.2%				
Profit for the year	12.5%	30.1	12.0%	28.8		-1.3	-4.2%				
Profit attributable to owners of the Company	12.7%	30.6	12.2%	29.2	(44.2%)	-1.4	-4.7%	7.1%	66.0	12.5	+23.4%
Tax rate		33.4%		31.8%							
Overseas sales ratio		42.0%		37.6%							
<u>Currency Rate (Average)</u>								<u>Currency Rate (Average)</u>			
USD/JPY		108.25		111.10				USD			
EUR/JPY		122.17		122.19				EUR			

Forex impact: +1.8
(USD:+1.4, ASCA:+0.4)

Forex impact: +0.6
(USD:+0.5)

Forex impact: +0.6
(USD:+0.5)

Forex impact: +0.5
(USD:+0.5)

Forex impact: +0.1

Improvement in forex gains/losses

*This report is not subject to audit procedures.

*Special items : Items having a transitory and material impact on operating profit are defined as "Special items".

Specifically, gains and losses related to: sale of fixed assets, restructuring, impairment, litigation, etc. amounting to 1 billion JPY or more are defined as "Special items".

Annual impact of one yen change

	Forecast	
	USD	EUR
Revenue	1.5 JPY Bn	0.5 JPY Bn
Operating Profit	-0.4 JPY Bn	minor

2. Revenue of Global Products

JPY Bn		FY2016 Q1	FY2017 Q1				FY2017		
		Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)
Olmesartan	antihypertensive agent	65.7	42.8	(32.0%)	-22.8	-34.8%	134.0	-84.0	-38.5%
	Olmetec (JPN)	18.3	16.8	(35.8%)	-1.4	-7.9%	47.0	-22.4	-32.3%
	Rezaltas (JPN)	4.7	4.5	(28.1%)	-0.2	-3.7%	16.0	-1.5	-8.7%
	Olmesartan (US)	23.2	6.8	(48.4%)	-16.4	-70.7%	14.0	-52.4	-78.9%
	Olmesartan (EU)	14.0	9.0	(34.5%)	-5.0	-35.8%	26.0	-17.2	-39.8%
	Other subsidiaries, export, etc	5.6	5.8	(18.7%)	0.2	+3.0%	31.0	9.5	+44.2%
Edoxaban	anticoagulant	7.3	15.3	(23.5%)	8.0	+108.9%	65.0	27.7	+74.1%
	Lixiana (JPN)	5.5	9.4	(24.0%)	3.9	+69.9%	39.0	14.0	+56.0%
	Savaysa (US)	0.3	0.5	(24.1%)	0.2	+61.5%	2.0	0.1	+6.6%
	Lixiana (EU)	1.4	4.9	(22.3%)	3.5	+238.5%	22.0	12.3	+127.5%
	Other subsidiaries	0.1	0.6	(28.2%)	0.5	+666.5%	2.0	1.2	+155.9%
Prasugrel	antiplatelet agent	10.9	11.5	-	0.7	+6.0%	not disclosed	-	-
	Effient alliance revenue (US)	6.0	6.1	-	0.1	+2.0%	not disclosed	-	-
	Efient (EU)	2.3	1.9	(27.2%)	-0.4	-17.0%	7.0	-0.9	-11.9%
	Efient (JPN)	2.5	3.3	(25.4%)	0.8	+33.8%	13.0	2.6	+24.8%
	Other subsidiaries, export, etc	0.2	0.2	-	0.1	+57.0%	not disclosed	-	-

3. Revenue by Business Units and Products (1)

JPY Bn

	FY2016 Q1		FY2017 Q1				FY2017		
	Results		Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)
Japan	123.4		130.0	(24.3%)	6.6	+5.4%	536.0	29.4	+5.8%
Nexium	21.0		22.6	(24.6%)	1.5	+7.4%	92.0	8.0	+9.5%
Memory	12.1		12.5	(23.2%)	0.4	+3.3%	54.0	7.1	+15.2%
Olmotec	18.3		16.8	(35.8%)	-1.4	-7.9%	47.0	-22.4	-32.3%
Lixiana	5.5		9.4	(24.0%)	3.9	+69.9%	39.0	14.0	+56.0%
Loxonin	10.3		9.6	(29.0%)	-0.7	-7.2%	33.0	-4.4	-11.8%
Tenelia	6.7		7.6	(25.3%)	0.9	+14.3%	30.0	5.8	+24.1%
Pralia	4.1		5.5	(23.9%)	1.4	+33.6%	23.0	5.0	+28.1%
Rezaltas	4.7		4.5	(28.1%)	-0.2	-3.7%	16.0	-1.5	-8.7%
Ranmark	3.4		3.8	(25.1%)	0.4	+12.0%	15.0	1.1	+7.7%
Efient	2.5		3.3	(25.4%)	0.8	+33.8%	13.0	2.6	+24.8%
Inavir	0.6		0.7	(5.5%)	0.2	+28.7%	13.0	-6.6	-33.5%
Cravit	3.8		3.3	(25.4%)	-0.4	-11.9%	13.0	-2.1	-13.9%
Urief	3.0		2.9	(26.3%)	-0.1	-3.7%	11.0	-0.4	-3.7%
Omnipaque	3.7		3.6	(33.1%)	-0.0	-0.6%	11.0	-3.2	-22.5%
Mevalotin	2.9		2.4	(24.5%)	-0.5	-16.5%	10.0	-0.4	-4.3%
Daiichi Sankyo Espha products	5.2		7.2	-	2.0	+37.8%	not disclosed	-	-
Vaccines business	6.6		7.6	-	0.9	+13.8%	not disclosed	-	-
Daiichi Sankyo Healthcare (OTC)	14.8		16.8	(24.4%)	2.0	+13.8%	69.0	2.3	+3.4%

3. Revenue by Business Units and Products (2)

JPY Bn	FY2016 Q1		FY2017 Q1				FY2017		
	Results		Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)
Daiichi Sankyo, Inc. (US)	40.7		25.0	(40.3%)	-15.7	-38.7%	62.0	-80.3	-56.4%
Olmesartan	antihypertensive agent	23.2	6.8	(48.4%)	-16.4	-70.7%	14.0	-52.4	-78.9%
Welchol	hypercholesterolemia treatment/ type 2 diabetes mellitus treatment	10.0	10.1	(37.5%)	0.2	+1.5%	27.0	-18.5	-40.7%
Effient	antiplatelet agent	6.0	6.1	-	0.1	+2.0%	not disclosed	-	-
Savaysa	anticoagulant	0.3	0.5	(24.1%)	0.2	+61.5%	2.0	0.1	+6.6%
Movantik	opioid-induced constipation treatment	0.9	1.3	-	0.4	+46.5%	not disclosed	-	-
Luitpold Pharmaceuticals, Inc. (US)	22.0		27.6	(26.8%)	5.6	+25.5%	103.0	14.9	+16.9%
Venofer	treatment for iron deficiency anemia	7.4	7.4	(26.4%)	0.0	+0.2%	28.0	-0.5	-1.6%
Injectafer	treatment for iron deficiency anemia	5.9	8.1	(24.4%)	2.1	+35.9%	33.0	9.0	+37.7%
Daiichi Sankyo Europe GmbH	20.4		18.5	(28.1%)	-1.9	-9.4%	66.0	-5.0	-7.0%
Olmesartan	antihypertensive agent	14.0	9.0	(34.5%)	-5.0	-35.8%	26.0	-17.2	-39.8%
Efient	antiplatelet agent	2.3	1.9	(27.2%)	-0.4	-17.0%	7.0	-0.9	-11.9%
Lixiana	anticoagulant	1.4	4.9	(22.3%)	3.5	+238.5%	22.0	12.3	+127.5%
Asia, South and Central America (ASCA)	17.7		19.0	(22.6%)	1.2	+7.0%	84.0	11.9	+16.4%
Daiichi Sankyo China		8.2	8.3	-	0.1	+1.2%	not disclosed	-	-
Daiichi Sankyo Taiwan		1.3	1.6	-	0.3	+26.4%	not disclosed	-	-
Daiichi Sankyo Korea		2.1	2.9	-	0.8	+37.4%	not disclosed	-	-
Daiichi Sankyo Thailand		0.6	0.6	-	0.0	+7.3%	not disclosed	-	-
Daiichi Sankyo Brasil Farmacêutica		2.0	2.4	-	0.4	+18.7%	not disclosed	-	-

3. Revenue by Business Units and Products (3)

[Reference] Revenue in Local Currency

USD Mn

	FY2016 Q1	FY2017 Q1				FY2017		
	Results	Results	(vs. Forecast (%))	YoY	YoY (%)	Forecast	YoY	YoY (%)
Daiichi Sankyo, Inc. (US)	376	225	(39.9%)	-151	-40.2%	564	-749	-57.1%
Olmesartan antihypertensive agent	214	61	(48.0%)	-153	-71.5%	127	-485	-79.2%
Welchol hypercholesterolemia treatment/ type 2 diabetes mellitus treatment	92	91	(37.2%)	-1	-1.1%	245	-174	-41.5%
Effient antiplatelet agent	55	55	-	-0	-0.6%	not disclosed	-	-
Savaysa anticoagulant	3	4	(23.9%)	2	+57.4%	18	1	+5.0%
Movantik opioid-induced constipation treatment	8	12	-	4	+42.7%	not disclosed	-	-

USD Mn

Luitpold Pharmaceuticals, Inc. (US)	203	248	(26.5%)	45	+22.3%	936	124	+15.2%
Venofer treatment for iron deficiency anemia	68	67	(26.2%)	-2	-2.4%	255	-8	-3.1%
Injectafer treatment for iron deficiency anemia	55	72	(24.2%)	18	+32.4%	300	79	+35.7%

EUR Mn

Daiichi Sankyo Europe GmbH	167	152	(27.6%)	-16	-9.4%	550	-47	-7.9%
Olmesartan antihypertensive agent	114	73	(33.9%)	-41	-35.8%	217	-147	-40.4%
Efient antiplatelet agent	19	16	(26.7%)	-3	-17.0%	58	-9	-12.8%
Lixiana anticoagulant	12	40	(21.9%)	28	+238.5%	183	102	+125.3%

4. Consolidated Statement of Financial Position

<Assets>

JPY Bn

	Mar. 2017	Jun. 2017	vs. Mar. 2017
Assets			
Current assets			
Cash and cash equivalents	246.1	265.2	19.2
Trade and other receivables	231.9	236.6	4.7
Other financial assets	552.9	504.9	-48.0
Inventories	153.1	165.3	12.2
Other current assets	10.5	12.2	1.8
Subtotal	1,194.4	1,184.2	-10.2
Assets held for sale	3.4	2.6	-0.8
Total current assets	1,197.8	1,186.7	-11.0
Non-current assets			
Property, plant and equipment	217.8	216.7	-1.0
Goodwill	78.4	78.3	-0.1
Intangible assets	217.0	217.9	0.9
Investments accounted for using the equity method	1.4	1.2	-0.2
Other financial assets	140.9	181.4	40.5
Deferred tax assets	53.5	50.1	-3.5
Other non-current assets	8.1	7.9	-0.3
Total non-current assets	717.2	753.6	36.4
Total assets	1,915.0	1,940.3	25.4
* Liquidity on hand	798.2	769.3	-28.9
Debt with interest	282.1	282.1	-0.1
Net Cash	516.1	487.2	-28.8

Acquisition +4.7, Depreciation -6.0

Acquisition +6.3, Amortization -4.6

<Liabilities and equity>

JPY Bn

	Mar. 2017	Jun. 2017	vs. Mar. 2017
Liabilities			
Current liabilities			
Trade and other payables	219.8	194.7	-25.1
Bonds and borrowings	-	-	-
Other financial liabilities	0.5	0.5	-0.0
Income taxes payable	58.0	60.4	2.5
Provisions	41.2	37.6	-3.6
Other current liabilities	6.3	8.6	2.3
Subtotal	325.8	301.8	-24.0
Liabilities directly associated with assets held for sale	1.1	1.1	-
Total current liabilities	326.8	302.9	-24.0
Non-current liabilities			
Bonds and borrowings	280.5	280.5	0.0
Other financial liabilities	9.1	12.1	3.1
Post employment benefit liabilities	11.4	11.7	0.3
Provisions	16.4	49.6	33.2
Deferred tax liabilities	32.3	32.0	-0.3
Other non-current liabilities	67.1	65.5	-1.6
Total non-current liabilities	416.7	451.4	34.7
Total liabilities	743.6	754.2	10.7
Equity			
Equity attributable to owners of the Company			
Share capital	50.0	50.0	-
Capital surplus	103.8	103.8	-
Treasury shares	-114.0	-113.9	0.0
Other components of equity	124.5	133.7	9.2
Retained earnings	1,011.6	1,017.4	5.8
Total equity attributable to owners of the Company	1,175.9	1,190.9	15.0
Non-controlling interests			
Non-controlling interests	-4.5	-4.8	-0.4
Total equity	1,171.4	1,186.1	14.7
Total liabilities and equity	1,915.0	1,940.3	25.4

Profit for the period +29.2,
Payment of dividends -23.2

5. Consolidated Statement of Cash Flows

JPY Bn

	FY2016 Q1	FY2017 Q1	YoY
Cash flows from operating activities			
Profit before tax	45.2	42.2	-3.0
Depreciation and amortization	10.9	10.6	-0.2
(Increase) decrease in receivables and payables	-10.3	-27.8	-17.5
Others, net	-6.3	-15.4	-9.1
Income taxes paid	-6.5	-10.0	-3.5
Net cash flows from operating activities	33.0	-0.3	-33.3
Cash flows from investing activities			
Net (increase) decrease in time deposits and securities	58.0	49.9	-8.2
(Acquisition of) proceeds from sales of fixed assets	-6.9	-9.4	-2.5
Proceeds from sale of subsidiary	-	-	-
Net (increase) decrease in investment securities	-0.8	-1.0	-0.2
Others, net	0.0	0.6	0.6
Net cash flows from investing activities	50.4	40.1	-10.3
Cash flows from financing activities			
Net (increase) decrease in borrowings	-	-	-
Proceeds from bonds and borrowings	-	-	-
Purchase of treasury shares	-7.3	-0.0	7.3
Dividends paid	-20.5	-23.2	-2.7
Others, net	-6.8	-0.1	6.7
Net cash flows from financing activities	-34.7	-23.4	11.3
Net increase (decrease) in cash and cash equivalents	48.6	16.4	-32.2
Cash and cash equivalents at the beginning of the period	222.2	246.1	23.9
Effect of exchange rate changes on cash and cash equivalents	-11.9	2.8	14.7
Cash and cash equivalents at the end of the period	258.9	265.2	6.3
* Free cash flows (Cash flows from operating activities and investing activities)	83.3	39.7	-43.6

FY2016: Purchase of treasury shares

6. Number of Employees

	Jun. 2016	Mar. 2017	Jun. 2017
	Results	Results	Results
Consolidated	15,306	14,670	14,827
Japan	8,762	8,648	8,865
North America	2,523	2,464	2,486
Europe	1,859	1,578	1,540
Others	2,162	1,980	1,936

7. Capital Expenditure, Depreciation and Amortization

	JPY Bn	FY2016 Q1	FY2016	FY2017 Q1	FY2017
		Results	Results	Results	Forecast
Capital expenditure		3.9	23.9	4.5	35.5
Depreciation and amortization		10.9	47.4	10.6	43.5
Property, plant and equipment		7.3	31.1	6.0	-
Intangible assets		3.6	16.3	4.6	-

8. Summary of Product Outlines

Brand Name	Generic Name	Therapeutic Category	Launched	Origin	Marketing Alliance	Type of Alliance
Japan						
Nexium	esomeprazole	ulcer treatment	2011	AstraZeneca	AstraZeneca	Co-promotion (DS: Sales)
Memary	memantine	Alzheimer's disease treatment	2011	Merz		
Olmotec	olmesartan	antihypertensive agent	2004	Daiichi Sankyo		
Lixiana	edoxaban	anticoagulant	2011	Daiichi Sankyo		
Loxonin			1986	Daiichi Sankyo		
Loxonin Poultice			2006	Lead Chemical		
Loxonin Tape	loxoprofen	anti-inflammatory analgesic	2008	Lead Chemical		
Loxonin Gel			2010	Daiichi Sankyo		
Tenelia	teneligliptin	type 2 diabetes mellitus treatment	2012	Mitsubishi Tanabe	Mitsubishi Tanabe	Co-promotion (DS: Sales)
Pralia	denosumab	treatment for osteoporosis	2013	Amgen		
Rezaltas	olmesartan / azelnidipine	antihypertensive agent	2010	Daiichi Sankyo		
Ranmark	denosumab	treatment for bone complications caused by bone metastases from tumors	2012	Amgen		
Efient	prasugrel	antiplatelet agent	2014	Daiichi Sankyo Ube Industries		
Inavir	laninamivir	anti-influenza treatment	2010	Daiichi Sankyo		
Cravit	levofloxacin	synthetic antibacterial agent	1993	Daiichi Sankyo		
Urief	silodosin	treatment for dysuria	2006	Kissei	Kissei	Co-marketing
Omnipaque	iohexol	contrast medium	1987	GE Healthcare		
Mevalotin	pravastatin	antihyperlipidemic agent	1989	Daiichi Sankyo		
Daiichi Sankyo, Inc. (US)						
Olmесartan						
Benicar	olmesartan		2002			
Benicar HCT	olmesartan / hydrochlorothiazide		2003			
Azor	olmesartan / amlodipine	antihypertensive agent	2007	Daiichi Sankyo		
Tribenzor	olmesartan / amlodipine / hydrochlorothiazide		2010			
Welchol	colesevelam	hypercholesterolemia treatment/ type 2 diabetes mellitus treatment	2000	Genzyme		
Effient	prasugrel	antiplatelet agent	2009	Daiichi Sankyo Ube Industries	Lilly	Co-promotion (DS: Co-pro revenue)
Savaysa	edoxaban	anticoagulant	2015	Daiichi Sankyo		
Movantik	naloxegol	opioid-induced constipation treatment	2015	Nektar AstraZeneca	AstraZeneca	Co-promotion (DS: Co-pro revenue)
Luitpold Pharmaceuticals, Inc. (US)						
Venofer	iron sucrose injection	treatment for iron deficiency anemia	2000	Vifor Pharma	Fresenius	Co-marketing
Injectafer	ferric carboxymaltose injection	treatment for iron deficiency anemia	2013	Vifor Pharma	Daiichi Sankyo, Inc.	Promotion (Daiichi Sankyo, Inc.)
Daiichi Sankyo Europe GmbH						
Olmесartan						
Olmotec	olmesartan		2002			
Olmotec Plus	olmesartan / hydrochlorothiazide		2005			
Sevikar	olmesartan / amlodipine	antihypertensive agent	2009	Daiichi Sankyo	Menarini Pfizer	Co-marketing
Sevikar HCT	olmesartan / amlodipine / hydrochlorothiazide		2010			
Efient	prasugrel	antiplatelet agent	2009	Daiichi Sankyo Ube Industries		
Lixiana	edoxaban	anticoagulant	2015	Daiichi Sankyo	Merck (MSD)	Co-marketing

<9. Quarterly Data>

1. Consolidated Statement of Profit or Loss

JPY Bn	FY2016	FY2016	FY2016	FY2016	FY2016				FY2017	FY2017	FY2017	FY2017	FY2017	
	Q1	Q2	Q3	Q4	to revenue	Results	YoY	YoY (%)	Q1	Q2	Q3	Q4	to revenue	Results
	Results	Results	Results	Results					Results	Results	Results	Results		
Revenue	241.0	217.0	276.4	220.7	100.0%	955.1	-31.3	-3.2%	239.1				100.0%	239.1
Cost of sales	77.6	69.7	94.5	107.6	36.6%	349.4	30.8	+9.7%	80.1				33.5%	80.1
(excl. Special items)	77.6	69.7	94.5	83.4	34.0%	325.2	9.6	+3.0%	80.1				33.5%	80.1
(Special items)	-	-	-	24.2	2.5%	24.2	21.2	+697.2%	-				-	-
Gross Profit	163.4	147.4	181.9	113.1	63.4%	605.8	-62.1	-9.3%	159.0				66.5%	159.0
SG&A expenses	69.5	72.2	78.8	82.0	31.7%	302.5	-26.3	-8.0%	70.8				29.6%	70.8
(excl. Special items)	69.5	66.2	74.2	80.9	30.4%	290.8	-28.2	-8.8%	70.8				29.6%	70.8
(Special items)	-	6.0	4.6	1.1	1.2%	11.7	1.9	+19.1%	-				-	-
R&D expenses	46.6	49.2	47.7	70.9	22.4%	214.3	5.7	+2.7%	48.0				20.1%	48.0
(excl. Special items)	46.6	49.2	47.7	66.3	22.0%	209.8	6.8	+3.4%	48.0				20.1%	48.0
(Special items)	-	-	-	4.5	0.5%	4.5	-1.1	-19.8%	-				-	-
Operating Profit	47.3	26.0	55.4	-39.8	9.3%	88.9	-41.5	-31.8%	40.3				16.8%	40.3
(Operating Profit before Special items)	47.3	32.0	60.0	-10.0	13.5%	129.3	-19.6	-13.1%	40.3				16.8%	40.3
Financial income/expenses	-1.9	0.7	4.6	-4.8		-1.3	6.4		2.1					2.1
Share of profit or loss of investments accounted for using the equity method	-0.2	-0.0	0.4	-0.0		0.2	0.5		-0.1					-0.1
Profit before tax	45.2	26.7	60.5	-44.6	9.2%	87.8	-34.6	-28.3%	42.2				17.7%	42.2
Income taxes	15.1	9.0	21.0	-4.8		40.3	-1.7	-4.0%	13.4					13.4
Profit for the year	30.1	17.7	39.5	-39.8	5.0%	47.5	-32.9	-40.9%	28.8				12.0%	28.8
Profit attributable to owners of the Company	30.6	18.4	39.2	-34.7	5.6%	53.5	-28.8	-35.0%	29.2				12.2%	29.2
Tax rate	33.4%	33.7%	34.7%	10.7%		45.9%			31.8%					31.8%
Overseas sales ratio	42.0%	37.9%	37.6%	39.8%		39.3%			37.6%					37.6%
<u>Currency Rate (YTD Average)</u>														
USD/JPY	108.25	105.35	106.68	108.42		108.42			111.10					111.10
EUR/JPY	122.17	118.22	118.09	118.84		118.84			122.19					122.19

<9. Quarterly Data>

2. Revenue of Global Products

JPY Bn	FY2016 Q1	FY2016 Q2	FY2016 Q3	FY2016 Q4	FY2016			FY2017 Q1	FY2017 Q2	FY2017 Q3	FY2017 Q4	FY2017
	Results	Results	Results	Results	Results	YoY	YoY (%)	Results	Results	Results	Results	Results
Olmesartan	65.7	49.7	63.7	38.9	218.0	-66.1	-23.3%	42.8				42.8
Olmotec (JPN)	18.3	16.6	19.2	15.3	69.4	-4.4	-6.0%	16.8				16.8
Rezaltas (JPN)	4.7	4.2	4.8	3.9	17.5	-0.6	-3.5%	4.5				4.5
Olmesartan (US)	23.2	13.5	24.3	5.4	66.4	-45.3	-40.6%	6.8				6.8
Olmesartan (EU)	14.0	10.7	10.0	8.6	43.2	-15.7	-26.7%	9.0				9.0
Other subsidiaries, export, etc	5.6	4.7	5.5	5.7	21.5	-0.1	-0.4%	5.8				5.8
Edoxaban	7.3	8.7	9.9	11.3	37.3	22.3	+148.5%	15.3				15.3
Lixiana (JPN)	5.5	6.0	6.4	7.1	25.0	12.0	+92.6%	9.4				9.4
Savaysa (US)	0.3	0.6	0.5	0.5	1.9	1.4	+317.0%	0.5				0.5
Lixiana (EU)	1.4	1.9	2.8	3.5	9.7	8.1	+525.7%	4.9				4.9
Other subsidiaries	0.1	0.3	0.2	0.2	0.8	0.7	-	0.6				0.6
Prasugrel	10.9	9.3	10.9	10.5	41.6	9.4	+29.2%	11.5				11.5
Effient alliance revenue (US)	6.0	4.9	5.7	5.7	22.2	1.5	+7.2%	6.1				6.1
Efient (EU)	2.3	1.9	1.9	1.9	7.9	2.6	+47.9%	1.9				1.9
Efient (JPN)	2.5	2.4	2.9	2.6	10.4	5.5	+112.7%	3.3				3.3
Other subsidiaries, export, etc	0.2	0.2	0.4	0.3	1.0	-0.2	-14.6%	0.2				0.2

3. Revenue by Business Units and Products (1)	FY2016 Q1	FY2016 Q2	FY2016 Q3	FY2016 Q4	FY2016			FY2017 Q1	FY2017 Q2	FY2017 Q3	FY2017 Q4	FY2017
	Results	Results	Results	Results	Results	YoY	YoY (%)	Results	Results	Results	Results	Results
JPY Bn												
Japan	123.4	115.6	151.2	116.3	506.6	11.9	+2.4%	130.0				130.0
Nexium	21.0	21.0	25.4	16.6	84.0	1.6	+1.9%	22.6				22.6
Memary	12.1	11.3	12.9	10.5	46.9	4.4	+10.4%	12.5				12.5
Olmotec	18.3	16.6	19.2	15.3	69.4	-4.4	-6.0%	16.8				16.8
Lixiana	5.5	6.0	6.4	7.1	25.0	12.0	+92.6%	9.4				9.4
Loxonin	10.3	8.5	10.5	8.1	37.4	-10.7	-22.3%	9.6				9.6
Tenelia	6.7	5.1	7.9	4.5	24.2	7.6	+46.1%	7.6				7.6
Pralia	4.1	4.2	5.0	4.7	18.0	5.5	+44.1%	5.5				5.5
Rezaltas	4.7	4.2	4.8	3.9	17.5	-0.6	-3.5%	4.5				4.5
Ranmark	3.4	3.4	3.8	3.3	13.9	1.5	+12.4%	3.8				3.8
Efient	2.5	2.4	2.9	2.6	10.4	5.5	+112.7%	3.3				3.3
Inavir	0.6	0.0	7.4	11.6	19.6	5.5	+39.3%	0.7				0.7
Cravit	3.8	3.6	4.7	3.1	15.1	-3.3	-17.8%	3.3				3.3
Urief	3.0	2.7	3.1	2.5	11.4	-0.4	-3.4%	2.9				2.9
Omnipaque	3.7	3.5	3.9	3.1	14.2	-2.7	-15.9%	3.6				3.6
Mevalotin	2.9	2.5	2.8	2.2	10.4	-3.0	-22.2%	2.4				2.4
Daiichi Sankyo Espha products	5.2	4.7	5.8	4.5	20.2	1.7	+9.2%	7.2				7.2
Vaccines business	6.6	8.0	16.6	7.3	38.5	1.7	+4.7%	7.6				7.6
Daiichi Sankyo Healthcare (OTC)	14.8	17.4	19.7	14.9	66.7	13.4	+25.0%	16.8				16.8

3. Revenue by Business Units and Products (2)	FY2016 Q1	FY2016 Q2	FY2016 Q3	FY2016 Q4	FY2016			FY2017 Q1	FY2017 Q2	FY2017 Q3	FY2017 Q4	FY2017
	Results	Results	Results	Results	Results	YoY	YoY (%)	Results	Results	Results	Results	Results
JPY Bn												
Daiichi Sankyo, Inc. (US)	40.7	29.6	45.5	26.5	142.3	-42.8	-23.1%	25.0				25.0
Olmesartan	23.2	13.5	24.3	5.4	66.4	-45.3	-40.6%	6.8				6.8
Welchol	10.0	9.5	12.7	13.3	45.5	-2.9	-6.0%	10.1				10.1
Effient	6.0	4.9	5.7	5.7	22.2	1.5	+7.2%	6.1				6.1
Savaysa	0.3	0.6	0.5	0.5	1.9	1.4	+317.0%	0.5				0.5
Movantik	0.9	0.9	1.1	1.2	4.2	2.1	+106.8%	1.3				1.3
Luitpold Pharmaceuticals, Inc. (US)	22.0	19.8	22.5	23.8	88.1	-2.9	-3.2%	27.6				27.6
Venofer	7.4	6.5	7.4	7.2	28.5	-2.8	-8.8%	7.4				7.4
Injectafer	5.9	5.2	6.1	6.7	24.0	5.3	+28.6%	8.1				8.1
Daiichi Sankyo Europe GmbH	20.4	16.5	17.4	16.6	71.0	-6.8	-8.8%	18.5				18.5
Olmesartan	14.0	10.7	10.0	8.6	43.2	-15.7	-26.7%	9.0				9.0
Efient	2.3	1.9	1.9	1.9	7.9	2.6	+47.9%	1.9				1.9
Lixiana	1.4	1.9	2.8	3.5	9.7	8.1	+525.7%	4.9				4.9
Asia, South and Central America (ASCA)	17.7	16.3	18.4	19.7	72.1	-3.2	-4.2%	19.0				19.0
Daiichi Sankyo China	8.2	7.3	8.1	10.2	33.8	-0.5	-1.3%	8.3				8.3
Daiichi Sankyo Taiwan	1.3	1.2	1.3	1.4	5.2	-0.2	-3.3%	1.6				1.6
Daiichi Sankyo Korea	2.1	2.0	2.2	2.5	8.8	-0.5	-5.2%	2.9				2.9
Daiichi Sankyo Thailand	0.6	0.5	0.8	0.7	2.5	-1.5	-37.4%	0.6				0.6
Daiichi Sankyo Brasil Farmacêutica	2.0	2.1	2.7	2.0	8.8	0.7	+9.1%	2.4				2.4

3. Revenue by Business Units and Products (3)

[Reference] Revenue in Local Currency

	FY2016 Q1	FY2016 Q2	FY2016 Q3	FY2016 Q4	FY2016			FY2017 Q1	FY2017 Q2	FY2017 Q3	FY2017 Q4	FY2017
	Results	Results	Results	Results	Results	YoY	YoY (%)	Results	Results	Results	Results	Results
USD Mn												
Daiichi Sankyo, Inc. (US)	376	291	419	227	1,312	-228	-14.8%	225				225
Olmesartan	214	134	223	41	612	-317	-34.1%	61				61
Welchol	92	92	117	118	420	17	+4.2%	91				91
Effient	55	48	52	50	205	32	+18.7%	55				55
Savaysa	3	6	5	4	17	14	+362.1%	4				4
Movantik	8	9	10	11	38	22	+129.2%	12				12
USD Mn												
Luitpold Pharmaceuticals, Inc. (US)	203	193	206	210	812	55	+7.2%	248				248
Venofer	68	63	67	63	263	3	+1.0%	67				67
Injectafer	55	51	56	60	221	66	+42.5%	72				72
EUR Mn												
Daiichi Sankyo Europe GmbH	167	145	148	137	597	10	+1.8%	152				152
Olmesartan	114	94	85	70	363	-81	-18.2%	73				73
Efient	19	17	16	16	67	26	+65.0%	16				16
Lixiana	12	16	24	29	81	70	+598.0%	40				40

<10. Historical Data>

1. Revenue of Global Products

	FY2012	FY2013	FY2014	FY2015	FY2016
JPY Bn	Results	Results	Results	Results	Results
Olmesartan	258.9	300.2	293.5	284.1	218.0
Olmetec (JPN)	78.3	79.1	76.3	73.9	69.4
Rezaltas (JPN)	16.9	18.5	18.4	18.2	17.5
Benicar/Benicar HCT (US)	73.2	85.9	77.0	79.5	46.6
Azor (US)	14.8	17.4	18.3	19.7	11.2
Tribenzor (US)	6.8	9.0	11.3	12.4	8.6
Olmetec/Olmetec Plus (EU)	32.6	44.5	37.8	32.8	21.9
Sevikar (EU)	10.8	13.5	17.6	16.5	12.4
Sevikar HCT (EU)	4.7	7.6	9.9	9.6	9.0
Other subsidiaries, export, etc	20.7	24.7	27.0	21.6	21.5
Edoxaban	-	0.4	4.3	15.0	37.3
Lixiana (JPN)	-	0.4	3.6	13.0	25.0
Savaysa (US)	-	-	0.7	0.4	1.9
Lixiana (EU)	-	-	-	1.5	9.7
Other subsidiaries	-	-	-	0.0	0.8
Prasugrel	14.4	22.3	24.9	32.2	41.6
Effient alliance revenue (US)	10.5	15.4	17.6	20.7	22.2
Efient (EU)	3.9	4.7	4.8	5.4	7.9
Efient (JPN)	-	-	0.7	4.9	10.4
Other subsidiaries, export, etc	-	2.2	1.9	1.2	1.0

2. Revenue by Business Units and Products (1)

	FY2012	FY2013	FY2014	FY2015	FY2016
JPY Bn	Results	Results	Results	Results	Results
Japan	442.5	486.0	480.5	494.7	506.6
Nexium	21.6	54.2	69.3	82.4	84.0
Memary	23.8	33.3	36.8	42.4	46.9
Olmetec	78.3	79.1	76.3	73.9	69.4
Lixiana	0.3	0.4	3.6	13.0	25.0
Loxonin	59.6	59.3	49.5	48.1	37.4
Tenelia	1.3	1.5	7.6	16.5	24.2
Pralia	-	3.2	7.3	12.5	18.0
Rezaltas	16.9	18.5	18.4	18.2	17.5
Ranmark	4.4	8.1	10.2	12.4	13.9
Efient	-	-	0.7	4.9	10.4
Inavir	11.1	13.4	16.6	14.0	19.6
Cravit	35.9	33.5	27.8	18.4	15.1
Urief	11.1	11.4	11.5	11.8	11.4
Omnipaque	20.2	19.7	17.2	16.9	14.2
Mevalotin	25.8	21.5	16.2	13.4	10.4
Artist	22.4	22.4	18.1	15.1	10.6
Daiichi Sankyo Espha products	11.1	12.5	14.9	18.5	20.2
Vaccines business	39.1	37.5	32.2	36.8	38.5
Daiichi Sankyo Healthcare (OTC)	47.1	48.1	47.8	53.4	66.7

2. Revenue by Business Units and Products (2)

	FY2012	FY2013	FY2014	FY2015	FY2016
JPY Bn	Results	Results	Results	Results	Results
Daiichi Sankyo, Inc. (US)	142.3	171.8	173.0	185.1	142.3
Olmesartan	94.9	112.3	106.6	111.6	66.4
Benicar/Benicar HCT	73.2	85.9	77.0	79.5	46.6
Azor	14.8	17.4	18.3	19.7	11.2
Tribenzor	6.8	9.0	11.3	12.4	8.6
Welchol	33.1	42.3	47.4	48.4	45.5
Effient	10.5	15.4	17.6	20.7	22.2
Savaysa	-	-	0.7	0.4	1.9
Movantik	-	-	-	2.0	4.2
Luitpold Pharmaceuticals, Inc. (US)	38.6	39.6	57.4	91.0	88.1
Venofer	23.6	24.9	28.6	31.2	28.5
Injectafer	-	1.3	7.6	18.6	24.0
Daiichi Sankyo Europe GmbH	64.4	83.9	83.5	77.8	71.0
Olmesartan	48.0	65.6	65.2	58.9	43.2
Olmetec/Olmetec Plus	32.6	44.5	37.8	32.8	21.9
Sevikar	10.8	13.5	17.6	16.5	12.4
Sevikar HCT	4.7	7.6	9.9	9.6	9.0
Efient	3.9	4.7	4.8	5.4	7.9
Lixiana	-	-	-	1.5	9.7
Asia, South and Central America (ASCA)	45.4	58.8	67.5	75.3	72.1
Daiichi Sankyo China	16.4	21.2	27.4	34.2	33.8
Daiichi Sankyo Taiwan	3.3	4.5	4.9	5.4	5.2
Daiichi Sankyo Korea	5.3	9.1	8.9	9.3	8.8
Daiichi Sankyo Thailand	1.4	2.5	3.7	4.1	2.5
Daiichi Sankyo Brasil Farmacêutica	6.6	7.5	8.4	8.1	8.8
Daiichi Sankyo Venezuela	6.7	6.9	8.1	0.2	0.1

2. Revenue by Business Units and Products (3)**[Reference] Revenue in Local Currency**

	FY2012	FY2013	FY2014	FY2015	FY2016
	Results	Results	Results	Results	Results
USD Mn					
Daichi Sankyo, Inc. (US)	1,713	1,714	1,574	1,540	1,312
Olmesartan	1,142	1,120	969	929	612
Benicar/Benicar HCT	881	857	700	661	430
Azor	179	174	166	164	103
Tribenzor	82	90	103	103	79
Welchol	399	422	431	403	420
Effient	127	154	160	173	205
Savaysa	-	-	6	4	17
Movantik	-	-	-	17	38
USD Mn					
Luitpold Pharmaceuticals, Inc. (US)	465	395	522	758	812
Venofer	284	248	260	260	263
Injectafer	-	13	69	155	221
EUR Mn					
Daichi Sankyo Europe GmbH	601	624	602	587	597
Olmesartan	448	488	470	444	363
Olmetec/Olmetec Plus	304	331	272	248	184
Sevikar	100	100	127	124	104
Sevikar HCT	44	57	71	73	75
Efient	36	35	34	41	67
Lixiana	-	-	-	12	81

11. Major R&D Pipeline (Innovative pharmaceuticals)

As of July 2017

◆ Oncology (Late-stage pipeline products)

Generic Name/Project Code Number (Brand Name)	Class	Target indication	Region	Stage	Dosage Form	Partner	Target FY for approval/launch	Remarks
Denosumab/AMG 162	Anti-RANKL antibody	Breast cancer adjuvant	JP	P3	Injection	Amgen	2020	Additional indication
Ranmark (JP)	The fully human monoclonal antibody to target RANK Ligand, an essential mediator of osteoclast formation.							
Vemurafenib/PLX4032	BRAF inhibitor	Melanoma adjuvant	US/EU	P3	Oral	-	-	Additional indication. Licensee Roche is conducting the study. Submission in 2018 is planned.
Zelboraf	The molecular-targeted agent to inhibit BRAF V600E mutation.							
Quizartinib/AC220	FLT3-ITD inhibitor	Acute myeloid leukemia	US/EU/Asia	P3	Oral	-	2018	Relapsed and refractory AML patients
			US/EU/Asia	P3			2021-	Newly diagnosed AML patients
			JP	P2			2018-	Relapsed and refractory AML patients
Kinase inhibitor against a receptor-type tyrosine kinase, FLT3. Therapeutic effect for patients with acute myeloid leukemia harboring FLT3-ITD mutation is expected.								
Pexidartinib/PLX3397	CSF-1R/KIT/FLT3-ITD inhibitor	Tenosynovial Giant Cell Tumor (TGCT)	US/EU	P3	Oral	-	2019	Including pigmented villonodular synovitis
		Solid tumors	Asia	P1			-	Including TGCT
		Glioblastoma	US	P2			-	
		c-KIT Melanoma	Asia	P1/2			-	
		Melanoma, Solid tumors	US	P1/2			-	Merck & Co., Inc.
The molecular-targeted agent to inhibit CSF-1R, KIT and FLT3-ITD. This agent is expected to reduce tumor cell proliferation and expansion of metastases.								
Nimotuzumab/DE-766	Anti-EGFR antibody	Gastric cancer	JP	P3	Injection	InnoCIMA b Pte Ltd	2020	
The humanized monoclonal antibody to target Epidermal Growth Factor Receptor(EGFR). This antibody is expected to be a best in class EGFR, safety against the skin toxicity and the efficacy comparable to the other antibodies.								
Patritumab/U3-1287	Anti-HER3 antibody	Head & neck cancer	EU	P2	Injection	-	-	
The fully human monoclonal antibody to target HER3, one of the Epidermal Growth Factor Receptor (EGFR) family of proteins. HER3 is overexpressed in many tumors of epithelial origin and HER2/HER3 dimers and EGFR/HER3 dimers are expected more potent to induce tumor cell proliferation than homodimers of HER2 or EGFR.								
DS-1647(G47Δ)	Oncolytic HSV-1	Glioblastoma	JP	P2	Injection	ActiVec Inc.	-	Granted SAKIGAKE designation from MHLW. Investigator Initiated Study is on-going Orphan drug designation from MHLW in July 2017.
The third generation oncolytic herpes simplex virus type 1(HSV-1), genetically-engineered to restrict virus replication to tumor cells. This oncolytic virus therapy is expected equal or better safety and better efficacy profile compare to existing oncolytic virus.								

Underline: change after FY2016 Q4 Financial Announcement in May 2017

◆ Oncology (Early-stage pipeline products)

Generic Name/Project Code Number	Class	Target indication	Region	Stage	Partner	Target FY for approval/launch	Remarks
DS-3032	MDM2 inhibitor	Solid tumors	US/JP	P1	-	-	
		Leukemia	US	P1	-	-	
PLX7486	FMS/TRK inhibitor	Solid tumors	US	P1	-	-	
DS-8273	Anti-DR5 antibody	Solid tumors	US	P1	-	-	
PLX8394	BRAF inhibitor	Solid tumors	US	P1	-	-	
		Leukemia	US	P1	-	-	
DS-6051	NTRK/ROS1 inhibitor	Solid tumors	US/JP	P1	-	-	
PLX9486	KIT inhibitor	Solid tumors	US	P1	-	-	
DS-8201	Anti-HER2 antibody drug conjugate	Solid tumors	JP/US	P1	-	-	Granted Fast Track designation for HER2-positive metastatic breast cancer by U.S. FDA
DS-1123	Anti-FGFR2 antibody	Solid tumors	JP	P1	-	-	
DS-3201	EZH1/2 inhibitor	Non-Hodgkin's lymphoma	JP	P1	-	-	
		Acute myeloid leukemia	US	P1	-	-	
PLX73086/AC708	CSF-1R inhibitor	Tenosynovial Giant Cell Tumor (TGCT)	US	P1	-	-	
PLX51107	BRD4 inhibitor	Hematologic malignancies	US	P1	-	-	
U3-1402	Anti-HER3 antibody drug conjugate	Solid tumors	JP	P1	-	-	
DS-1001	IDH1 mutant inhibitor	Glioma	JP	P1	-	-	

Underline: change after FY2016 Q4 Financial Announcement in May 2017

◆ Cardiovascular-Metabolics (Late-stage pipeline products)

Generic Name/Project Code Number (Brand Name)	Class	Target indication	Region	Stage	Dosage Form	Partner	Target FY for approval/launch	Remarks
Edoxaban/DU-176b Lixiana (JP) LIXIANA (EU, Asia) SAVAYSA (US)	Factor Xa inhibitor	Atrial fibrillation (AF)	ASCA etc.	Submitted			-	BR (14/6*), CN(15/8) submitted * means June 2014, ditto
		Venous thromboembolism (VTE)	ASCA etc.	Submitted	Oral	-	-	BR (14/6), CN(15/8) submitted
		Elderly patients with non-valvular atrial fibrillation (AF)	JP	P3			2021	Additional dosage and formulation for elderly (80 years and older) AF patients
The once daily oral anti coagulant (FXa inhibitor) discovered by Daiichi Sankyo. Edoxaban specifically, reversibly and directly inhibits the enzyme, Factor Xa, a clotting factor in the blood.								
Prasugrel/CS-747 Effient (US, Asia) Efiect (JP, EU)	Anti-platelet agent	Ischemic stroke	JP	P3	Oral	Ube Industries	2018	Additional indication, phase 3 studies completed
The oral antiplatelet agent. Prasugrel helps to keep blood platelets from clumping together and developing a blockage in an artery.								
Esaxerenone/CS-3150	MR antagonist	Hypertension	JP	P3	Oral	Exelixis, Inc.	2019	
		Diabetic nephropathy	JP	P2b			-	
The agent inhibits aldosterone binding to Mineralocorticoid Receptor (MR) which stimulate the sodium absorption into kidney. This agent is expected to exhibit antihypertensive and organ-protective effect.								

Underline: change after FY2016 Q4 Financial Announcement in May 2017

◆ Cardiovascular-Metabolics (Early-stage pipeline products)

Generic Name/Project Code Number	Class	Target indication	Region	Stage	Partner	Target FY for approval/launch	Remarks
DS-1040	TAFIa inhibitor	Acute ischemic stroke, Acute pulmonary embolism	<u>US/EU/JP</u>	P1	-	-	
DS-2330	Hyperphosphatemia treatment	Hyperphosphatemia in chronic kidney disease (CKD)	-	P1	-	-	
DS-9231/TS23	α 2 plasmin inhibitor-inactivating antibody	Thrombosis (<u>Acute pulmonary embolism, ischemic stroke</u>)	-	P1	Translational Sciences, Inc.	-	In-lisencing from Translational Sciences, Inc.

Underline: change after FY2016 Q4 Financial Announcement in May 2017

◆ Internal Medicine (Late-stage pipeline products)

Generic Name/Project Code Number (Brand Name)	Class	Target indication	Region	Stage	Dosage Form	Partner	Target FY for approval/launch	Remarks
CL-108	Opioid μ -receptor agonist combination of antiemetic	Acute pain	US	Received CRL	Oral	Charleston Laboratories, Inc.	-	FDA issued Complete Response Letter in the end of January 2017
Combination product of immediate-release promethazine, hydrocodone and acetaminophen. Reduction of opioid-induced nausea and vomiting (OINV) is expected.								
Hydromorphone/DS-7113	Opioid μ -receptor agonist	Cancer pain	JP	Submitted	Injection		2017	Submitted by Daiichi Sankyo Propharma in February 2017 Drug with new route of administration
Narcotic analgesics. <u>Immediate and extended-release tablets were launched in Japan in June 2017.</u>								
Mirogabalin/DS-5565	$\alpha 2\delta$ ligand	Fibromyalgia	US/EU	P3	Oral	-	2019	<u>Announced top line result</u>
		Diabetic peripheral neuropathic pain	JP/Asia	P3			2018	
		Postherpetic neuralgia	JP/Asia	P3			2018	<u>Announced top line result</u>
The pain therapy agent to reduce the neurotransmitter release from nerve terminals. This agent is expected to show the good balanced efficacy and safety profile.								
Denosumab/AMG 162 Pralia (JP)	Anti-RANKL antibody	<u>Inhibition of the progression of bone erosion associated with rheumatoid arthritis</u>	JP	<u>Approved</u>	Injection	Amgen	2017	<u>Approved in July 2017</u>
The fully human monoclonal antibody to target RANK Ligand, an essential mediator of osteoclast formation.								
Laninamivir/CS-8958 Inavir (JP)	Neuraminidase inhibitor	Influenza	US/EU	P2	Inhalation	-	-	Out-licensing with Biota
			JP	P3			-	Additional dosage form, nebulizer formulation
The long-acting neuraminidase inhibitor and acts directly on the pulmonary and tracheal sites of infection.								

Underline: change after FY2016 Q4 Financial Announcement in May 2017

◆ Internal Medicine (Early-stage pipeline products)

Generic Name/Project Code Number	Class	Target indication	Region	Stage	Partner	Target FY for approval/launch	Remarks
DS-1971	Analgesic agent	Chronic pain	-	P1	-	-	
DS-1501	Anti-Siglec-15 antibody	Osteoporosis	US	P1	-	-	
DS-7080	Angiogenesis inhibitor	Neovascular age-related macular degeneration (AMD)	US	P1	-	-	
DS-2969	GyrB inhibitor	Clostridium difficile infection (CDI)	US	P1	-	-	Active in out-licensing
DS-5141	ENA oligonucleotide	Duchenne muscular dystrophy (DMD)	JP	P1/2	-	-	Granted SAKIGAKE designation from MHLW in April 2017

Underline: change after FY2016 Q4 Financial Announcement in May 2017

◆ Vaccines

Generic Name/Project Code Number (Brand Name)	Class	Target indication	Region	Stage	Dosage Form	Partner	Target FY for approval/launch	Remarks
VN-100	Intradermal seasonal influenza vaccine	Prevention of seasonal influenza	JP	Submitted	Injection*	Terumo Corporation	-	Submitted by Japan Vaccine in April 2015 * prefilled syringe
		The Vaccine is a pre-filled syringe type, intradermal influenza HA vaccine co-developed by four companies [Daiichi Sankyo, Terumo Corporation, Japan Vaccine and Kitasato Daiichi Sankyo Vaccine Co., Ltd.]. The intradermal injection device for this vaccine is developed by Terumo Corporation. This device, which offers a more easy-to-use, surefire method to administer the vaccine than current methods. The device is also expected to ease patient hesitation to be injected and lower the risk of damaging peripheral blood vessels and nerves within the subcutaneous tissue.						
VN-0107/MEDI3250	Live attenuated influenza vaccine	Prevention of seasonal influenza	JP	Submitted	Nasal spray	AstraZeneca/ MedImmune	-	Submitted by Daiichi Sankyo in June 2016
		The US brand name of this vaccine is FluMist Quadrivalent that is a live attenuated influenza vaccine which is administered as a nasal spray and contains four protective strains.						
VN-0105	DPT-IPV/Hib vaccine	Prevention of pertussis, diphtheria, tetanus, poliomyelitis and Hib	JP	P3	Injection	Sanofi Pasteur	2019	Co-develop with Sanofi K.K.and KDSV
		A combination vaccine reconstituting Hib with precipitated and purified pertussis-diphtheria-tetanus-inactivated polio vaccine (Salk vaccine) vaccine launched in Japan, as 1st in the class of pentavalent vaccine (DPT-IPV/Hib).						
VN-0102/JVC-001	Measles-Mumps-Rubella vaccine	Prevention of Measles, Mumps and Rubella	JP	P1/2	Injection	-	-	Japan vaccine company is conducting the phase 1/2 study

Underline: change after FY2016 Q4 Financial Announcement in May 2017

◆ Stage-up (major changes from the FY2016 Q4 Financial Announcement in May 2017)

Generic Name/Project Code Number	Class	Target indication	Current region/stage	Remarks
Denosumab/AMG 162 Pralia (JP)	Anti-RANKL antibody	Inhibition of the progression of bone erosion associated with rheumatoid arthritis	JP Approved	Approved in July 2017

◆ Discontinue (major changes from the FY2016 Q4 Financial Announcement in May 2017)

Generic Name/Project Code Number	Class	Target indication	Stage	Reason
Etanercept biosimilar/CHS-0214	TNFa inhibitor	Rheumatoid arthritis	JP P3	Decided to discontinue the submission due to unable to keep stable commercial supply

